Subcutaneous Administration of Otelixizumab to T1DM Patients
Status:
Completed
Trial end date:
2013-06-25
Target enrollment:
Participant gender:
Summary
This study will assess the subcutaneous administration of otelixizumab to T1DM patients. The
study will provide safety, tolerability, pharmacodynamic and pharmacokinetic information
which will enable the identification of appropriate safe and well-tolerated subcutaneous
dosage regimens to be used in subsequent clinical studies. This study will consist of a
screening phase, followed by an in-house phase whereby otelixizumab will be administered to
cohorts that will be staggered at each dose level.